Jose G. Trevino
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Directed acyclic graph for Cox proportional hazards regression. Directed acyclic graph representing all variables considered in building multivariable models for the Cox proportional hazards regression representing the associations of muscle changes with PDAC outcomes.
Year:
2025
Directed acyclic graph for generalized linear model. Directed acyclic graph representing all variables considered in building multivariable models for the generalized linear models representing the associations of PDAC diagnosis with post-diagnosis muscle changes.
Year:
2025
Background: Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no studies have quantified the impact of edema on tSMA and psoas skeletal muscle area (pSMA) changes. Thus, we sought to (i) assess the impact of edema on tSMA and pSMA changes between diagnosis and follow-up and (ii) explore the utility of pSMA as a clinically relevant measure of muscle and muscle loss among patients with PDAC. Methods: Body composition was measured using CT scans at diagnosis and follow-up from 95 patients enrolled in the Florida Pancreas Collaborative cohort study. Edema was assessed by opacifications in subcutaneous fat, and tSMA and pSMA changes were expressed as percent change between diagnosis and follow-up. We used multivariable generalized linear models to estimate mean tSMA and pSMA changes overall and by edema status. Spearman correlation was used to measure interrelationships of tSMA and pSMA. Results: tSMA increased between diagnosis and follow-up (Δ = 0.66) but only in patients with edema (Δ = 3.35) whereas non-edematous patients lost tSMA (Δ = −2.03). Conversely, pSMA decreased regardless of edema status. Furthermore, tSMA and pSMA were strongly correlated overall ( r = 0.75) and in non-edematous patients ( r = 0.83). Conclusions: Edema inflated estimates of tSMA at follow-up in patients with PDAC, but pSMA was impervious to edema and may represent a suitable proxy for tSMA. Impact: pSMA is a reliable measure of muscle and muscle loss and should be considered in future studies assessing muscle loss in patients with PDAC.
Year:
2025
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
Year:
2024
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Year:
2024
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Year:
2024
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
Year:
2024
PURPOSE Clinical trials determine safety and efficacy of cancer therapeutics and establish standards of care. Minority patient participation in cancer clinical trials is dismal. We aimed to determine the impact of eligibility criteria on disparities in pancreatic ductal adenocarcinoma (PDAC) clinical trial candidacy. METHODS Traditional PDAC trial eligibility criteria were obtained from ClinicalTrials.gov. Patients with PDAC who sought care at Virginia Commonwealth University Health from 2010 to 2019 were included. Clinical data were obtained from billing codes and discrete values in the electronic medical record. Eligibility criteria differences between racial groups were determined using chi-squared tests and unconditional maximum likelihood-based odds ratios. RESULTS Among 676 patients, most identified as Black or White race (42.5% and 51.6%, respectively). Using traditional criteria, Black patients were more likely to be ineligible for participation compared with White patients (42.4% v 33.2%, P = .023) secondary to hypoalbuminemia (14.1% v 7.9%, P = .023), HIV (3.1% v 0.3%, P = .010), hepatitis B (1.7% v 0%, P = .043), and hepatitis C (9.1% v 3.4%, P = .005). Black patients were also numerically more likely to be ineligible because of renal dysfunction, recent coronary stenting, and uncontrolled diabetes mellitus. Prior cancer treatment excluded fewer Black than White patients (9.1% v 14.0%, P = .072), most attributable to lower rates of neoadjuvant chemotherapy received. Strategic eligibility criteria revisions could equalize ineligibility rates between Black and White patients (26.8% v 24.8%, P = .581). CONCLUSION Traditional eligibility criteria differentially exclude Black patients from participating in PDAC clinical trials. These criteria perpetuate disparities, limit generalizability, and are often not medically justifiable. Revised criteria may improve participant diversity, without compromising safety or study results.
Year:
2022
Collaborators (33)
Lawrence Rubinstein
Statistician
National Cancer Institute
Sylvia Crowder
Assistant Member
H Lee Moffitt Cancer Center and Research Institute
Tiago Biachi de Castria
Associate Professor
University of South Florida
Xuefeng Wang
Associate Member/Professor
H Lee Moffitt Cancer Center and Research Institute
Michael A. Davies
-
Ghulam Rasool
Assistant Member
Moffitt Cancer Center
Min Jin Ha
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Vic VELANOVICH
University of South Florida
Sarah Judge
Research Assistant Professor
University of Florida
Jeffrey Chuang
Jackson Laboratory
Qianxing Mo
Senior Member
H Lee Moffitt Cancer Center and Research Institute
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Meenhard Herlyn
Professor, Director
The Wistar Institute
Xuelin Huang
Professor
The University of Texas MD Anderson Cancer Center
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Luis G Carvajal‐Carmona
Professor
University of California, Davis
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Kun Jiang
-
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Andrew Judge
Professor
University of Florida
J. Chuck Harrell
Virginia Commonwealth University
Jose Pimiento
H Lee Moffitt Cancer Center and Research Institute
Dung-Tsa Chen
H Lee Moffitt Cancer Center and Research Institute
Michael Lewis
Baylor College of Medicine
Paul Stewart
Research Associate Professor
University of Utah
Christopher J. Whelan
H Lee Moffitt Cancer Center and Research Institute
Soner Koc
GlaxoSmithKline Research and Development
Aleksandra Karolak
Assistant Professor - Secondary Appointment
Moffitt Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.